4baseCare

Two businesses sit under one name and only one is AI led. The core revenue engine is a genomics laboratory network running next generation sequencing panels, which is wet lab diagnostics rather than AI. OncoTwin, the clinical decision support layer that derives treatment insights from clinico genomic and outcomes linked data and is stated to learn continuously from real world results, is genuinely AI led. Buyers should be clear which they are purchasing, because the grade for the platform alone would be higher than the grade for the company as a whole.

Correctly positioned as decision support rather than autonomous decision making: the stated function is to support oncologists with faster and more confident insights, with the treating clinician retaining the therapy decision. Molecular tumor board intelligence is listed among the services, which situates the output inside an existing multidisciplinary review structure rather than around it. No disclosure was located on how model derived recommendations are presented against their evidence, so the reviewability of an individual recommendation is unverified.

The data strategy is disclosed clearly and the model is not. The company is specific that it builds population specific reference data, having developed a South Asian population specific cancer gene panel by profiling the whole exome and transcriptome of a stated 1,500 plus cancer patients across India, and it names custom in house algorithms for treatment recommendation. No model architecture, validation methodology, or performance figures for OncoTwin itself were located.

Evidence is stronger on the diagnostic side than the AI side. The assays are described as validated to detect somatic mutations with high sensitivity and specificity including low frequency alterations, the company reports more than 10,000 patients tested and collaborations with over 300 oncologists, and research has been presented at ASCO. Selection into the Memorial Sloan Kettering iHub program is a meaningful third party signal for OncoTwin specifically. What does not yet exist publicly is outcome evidence that OncoTwin's recommendations change treatment decisions or results, which is the claim that would move this grade.

No public data protection or PHI framework was located. The company handles genomic sequence data plus linked clinical outcomes across multiple national jurisdictions, which is among the most sensitive data combinations in this index, and the absence of published stewardship disclosure is a gap a buyer should close directly rather than assume is covered by lab accreditation.

No HIPAA or BAA posture published, which follows from the operating footprint: labs are in India, Dubai, Nepal, and the Philippines, and the applicable regimes are local data protection law rather than HIPAA. A United States institution engaging the company would need to establish HIPAA standing and cross border data transfer terms from scratch.

No SOC 2, ISO 27001, HITRUST, or equivalent information security attestation was located. Note the distinction that matters here: CAP accreditation covers laboratory quality, not information security, and the two should not be read as substitutes.

No FDA clearance is claimed and no United States regulatory pathway is evidenced, which is consistent with a company operating outside the United States market. The substantive quality credential is CAP accreditation from the College of American Pathologists, confirmed by CAP itself for the Dubai Science Park laboratory in March 2025 and stated for facilities across India. CAP accreditation is a real and verifiable standard for laboratory operations, but it is not a regulatory clearance of the AI platform, and buyers should not treat OncoTwin as carrying any device authorization.

Unusual and worth noting: bias is the company's stated founding thesis rather than an afterthought. It argues publicly that most genomic datasets and clinical trials overrepresent Caucasian populations, that cancer behaves differently across populations, and that this creates treatment discrepancies for South Asian patients, then builds population specific panels in response. That is a substantive engagement with representational bias that most vendors in this index never attempt. It stops short of an A because there is no published governance program, monitoring commitment, or measured performance comparison across the populations in question.

Integration is physical and organizational rather than technical: the hospital linked laboratory model places sequencing capability inside partner institutions including named hospitals in India, which shortens turnaround and embeds the company in the clinical pathway. AI powered medical record management is referenced as part of the patient platform. No HL7, FHIR, or named EHR integration was located, so a buyer should not assume results flow into the chart automatically.

The in hospital laboratory model is itself a data residency answer, and a deliberate one: the company describes moving away from shipping samples to centralized metro labs so that testing and analysis happen locally, with CAP accredited facilities in Bengaluru, Jammu, Kerala, Nepal, Dubai, and the Philippines. For institutions in markets with data localization requirements this is a genuine structural advantage. Cloud hosting and residency terms for the OncoTwin platform layer are not separately disclosed.

No published pricing for the genomic panels or for OncoTwin, and no disclosure of whether the platform is sold separately from testing or bundled with it. Reported company revenue figures and funding are public, but nothing that lets a buyer estimate cost.

Single specialty by design, which is oncology, spanning solid tumor profiling, ctDNA liquid biopsy, and hereditary germline risk testing, with services extending to molecular tumor board intelligence and clinical trial optimization. Geographic coverage is the more distinctive dimension: active in India, Dubai, Nepal, and the Philippines with stated plans to enter eight to ten additional countries. United States and European institutions are not the served market today.